Este artigo é um Preprint
Preprints são relatos preliminares de pesquisa que não foram certificados pela revisão por pares. Eles não devem ser considerados para orientar a prática clínica ou comportamentos relacionados à saúde e não devem ser publicados na mídia como informação estabelecida.
Preprints publicados online permitem que os autores recebam feedback rápido, e toda a comunidade científica pode avaliar o trabalho independentemente e responder adequadamente. Estes comentários são publicados juntamente com os preprints para qualquer pessoa ler e servir como uma avaliação pós-publicação.
Effectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalization among Finnish elderly and chronically ill - An interim analysis of a nationwide cohort study
Preprint
em Inglês
| medRxiv
| ID: ppmedrxiv-21258686
ABSTRACT
BackgroundIn Finland, both mRNA and adenovirus vector (AdV) Covid-19 vaccines have been used after the vaccination campaign started on December 27, 2020. Vaccination of the elderly and chronically ill was prioritized and the interval between doses set to 12 weeks. The objective of this interim analysis was to evaluate first and second dose vaccine effectiveness (VE) in a real-world setting. MethodsDuring the first 5 months of the campaign, a register-based cohort study was conducted in the Finnish elderly aged 70+ years and those aged 16-69 years with medical conditions predisposing to severe Covid-19 (chronically ill). Using Cox regression, VE against SARS-CoV-2 infection and Covid-19 hospitalization was estimated comparing the hazard in the vaccinated with that in the unvaccinated. ResultsThe cohorts included 901092 elderly (89% vaccinated) and 774526 chronically ill (69% vaccinated) individuals. Three weeks after the first dose, mRNA VE against infection was 45% (95% confidence interval, 36-53%) and 40% (26-51%) in elderly and chronically ill; mRNA VE against hospitalization was 63% (49-74%) and 82% (56-93%). In chronically ill, AdV VE was 42% (32-50) and 62% (42- 75%) against infection and hospitalization, respectively. One week after the second dose, mRNA VE against infection was 75% (65-82%) and 77% (65-85%) in elderly and chronically ill; mRNA VE against hospitalization was 93% (70-98%) and 90% (29-99%). ConclusionsCovid-19 vaccines protect against SARS-CoV-2 infection and Covid-19 hospitalization. A single dose provides moderate protection in elderly and chronically ill, although 2 doses are clearly superior. summaryThis register-based cohort study demonstrates that Covid-19 vaccines protect against SARS-CoV-2 infection and Covid-19 hospitalization among Finnish elderly and chronically ill. Vaccine effectiveness against hospitalization was moderate after 1 dose and increased to [≥]90% after 2 doses.
cc_by_nc_nd
Texto completo:
Disponível
Coleções:
Preprints
Base de dados:
medRxiv
Tipo de estudo:
Cohort_studies
/
Experimental_studies
/
Estudo observacional
/
Estudo prognóstico
Idioma:
Inglês
Ano de publicação:
2021
Tipo de documento:
Preprint